English

Adhera Therapeutics, Inc.

EDGAR

ATRX Quarterly report (10-Q) · filed 2023-11-20

163 filing records in this dataset, filed from 1995-11-13 to 2023-11-20. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

0 USD

2020 Q2 · USD

Exact inputs and evidence

Revenue: 0 USD Source

Operating cash flow

-96 thousand USD

2020 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -490000 USD Source
Operating Cash Flow: -394000 USD Source

Cash and cash equivalents: 32 thousand USD 2022-12-31 Source
Exact value

32000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 5.17 million shares 2023-09-30 Source
Exact value

5168912 shares

Reported share-count change

63.53% · 2.01 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

3160877 shares · 2022-09-30· Source
5168912 shares · 2023-09-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

183 thousand USD

2019-07-01 – 2020-06-30

Exact inputs and evidence

Revenue: 51000 USD · 2019-07-01 – 2019-09-30 Source
Revenue: 252000 USD · 2019-01-01 – 2019-12-31 Source
Revenue: 120000 USD · 2019-01-01 – 2019-09-30 Source
Revenue: 0 USD · 2020-01-01 – 2020-03-31 Source
Revenue: 0 USD · 2020-04-01 – 2020-06-30 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2023-11-20.

Financial data available through: 2022-12-31.

Coverage by financial measure

Revenue: 2 of 11 periods available· newest 2019-12-31
Operating income: 11 of 11 periods available· newest 2022-12-31
Net income: 11 of 11 periods available· newest 2022-12-31
Operating cash flow: 11 of 11 periods available· newest 2022-12-31
capital expenditure: No compatible figures in this window
Total assets: 11 of 11 periods available· newest 2022-12-31
Total liabilities: 10 of 11 periods available· newest 2022-12-31
Current assets: 11 of 11 periods available· newest 2022-12-31
Current liabilities: 11 of 11 periods available· newest 2022-12-31
Cash and cash equivalents: 6 of 11 periods available· newest 2022-12-31
long term debt: No compatible figures in this window
Shares outstanding: 11 of 11 periods available· newest 2022-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Net income
+USD 4.24 million

Prior period

−USD 6.35 million

2021-01-01 – 2021-12-31
Current period

−USD 2.11 million

2022-01-01 – 2022-12-31

Exact inputs and evidence

-2114000 − -6351000 = 4237000 USD

-6351000 USD · 2021-01-01 – 2021-12-31
Inspect prior input Prior source
-2114000 USD · 2022-01-01 – 2022-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Adhera Therapeutics, Inc. · 2022-12-31 Adhera Therapeutics, Inc. (edgar:737207) Year-over-year change in Net income: 4237000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T18:00:40Z Snapshot: d3571f4524df1cd7e461d9afe846975e6d696a6480f33c0e7aa5556fa861d83f Dimensions: Consolidated View: https://fundies.io/companies/edgar/737207?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -2114000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/737207/000149315223010160/form10-k.htm#1415165 Filing: 000149315223010160 Input fundies:NetIncome: -6351000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/737207/000149315223010160/form10-k.htm#1415523 Filing: 000149315223010160
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 735,000

Prior period

−USD 665,000

2021-01-01 – 2021-12-31
Current period

−USD 1.4 million

2022-01-01 – 2022-12-31

Exact inputs and evidence

-1400000 − -665000 = -735000 USD

-665000 USD · 2021-01-01 – 2021-12-31
Inspect prior input Prior source
-1400000 USD · 2022-01-01 – 2022-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Adhera Therapeutics, Inc. · 2022-12-31 Adhera Therapeutics, Inc. (edgar:737207) Year-over-year change in Operating cash flow: -735000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T18:00:40Z Snapshot: d3571f4524df1cd7e461d9afe846975e6d696a6480f33c0e7aa5556fa861d83f Dimensions: Consolidated View: https://fundies.io/companies/edgar/737207?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -1400000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/737207/000149315223010160/form10-k.htm#1307610 Filing: 000149315223010160 Input fundies:OperatingCashFlow: -665000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/737207/000149315223010160/form10-k.htm#1266795 Filing: 000149315223010160
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Revenue, Capital expenditure.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2019 2019-01-01 – 2019-12-31

Revenue USD 252,000 100% of revenue
Cost of revenue USD 409,000 162% of revenue
Operating expenses USD 11.16 million 4,428% of revenue
Operating income −USD 11.32 million −4,490% of revenue
Tax, interest and other Derived USD 662,000 263% of revenue
Net income −USD 11.98 million −4,753% of revenue

Cash

Operating cash flow −USD 8.74 million −3,467% of revenue
Capital expenditure Unavailable An input is unavailable.
Free cash flow Derived Unavailable An input is unavailable.

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2018 Operating loss: operating costs were 20,883% of revenue.
2019 Operating loss: operating costs were 4,590% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2018 2018-01-01 – 2018-12-31	76000	15871000 Derived	-15795000	960000 Derived	-16755000	Unavailable	Source 2018-01-01 – 2018-12-31: 76000 USD Inspect Revenue Open source 2018-01-01 – 2018-12-31: -15795000 USD Inspect Operating Income Open source 2018-01-01 – 2018-12-31: -16755000 USD Inspect Net Income Open source 2018-01-01 – 2018-12-31: -9611000 USD Inspect Operating Cash Flow Open source
2019 2019-01-01 – 2019-12-31	252000	11568000 Derived	-11316000	662000 Derived	-11978000	Unavailable	Source 2019-01-01 – 2019-12-31: 252000 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -11316000 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -11978000 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: -8738000 USD Inspect Operating Cash Flow Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 252K 2019

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20182018-12-31	Revenue	76000	Revenue: 76000 Open source
20192019-12-31	Revenue	252000	Revenue: 252000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

231.6% 2019

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20182018-12-31	Year over year	No prior comparable period	Revenue: 76000 Open source
20192019-12-31	Year over year	231.6%	Revenue: 252000 Open source Revenue: 76000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -4,490.5% 2019

Net margin -4,753.2% 2019

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20182018-12-31	Operating margin	-20,782.9%	Operating Income: -15795000 Open source Revenue: 76000 Open source
20192019-12-31	Operating margin	-4,490.5%	Operating Income: -11316000 Open source Revenue: 252000 Open source
20182018-12-31	Net margin	-22,046.1%	Net Income: -16755000 Open source Revenue: 76000 Open source
20192019-12-31	Net margin	-4,753.2%	Net Income: -11978000 Open source Revenue: 252000 Open source
20182018-12-31	Free cash flow margin	Not reported	Revenue: 76000 Open source Operating Cash Flow: -9611000 Open source
20192019-12-31	Free cash flow margin	Not reported	Revenue: 252000 Open source Operating Cash Flow: -8738000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -8.7M 2019

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20182018-12-31	Operating cash flow	-9611000	Operating Cash Flow: -9611000 Open source
20192019-12-31	Operating cash flow	-8738000	Operating Cash Flow: -8738000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

Not enough comparable data to show this history.

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20182018-12-31	Free cash flow	Unavailable	Operating Cash Flow: -9611000 Open source
20192019-12-31	Free cash flow	Unavailable	Operating Cash Flow: -8738000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

2,454% 2019

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20182018-12-31	Liabilities / assets	43.1%	Total Liabilities: 2214000 Open source Total Assets: 5141000 Open source
20192019-12-31	Liabilities / assets	2,454%	Total Liabilities: 10307000 Open source Total Assets: 420000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

0.04× 2019

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20182018-12-31	Current assets / current liabilities	2.11×	Current Assets: 4677000 Open source Current Liabilities: 2214000 Open source
20192019-12-31	Current assets / current liabilities	0.04×	Current Assets: 420000 Open source Current Liabilities: 10307000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2013 2013-01-01 – 2013-12-31	−USD 1.57 million Exact value Exact value: -1571000 USD 2013-01-01 – 2013-12-31: -1571000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Adhera Therapeutics, Inc. · 2013-12-31 Adhera Therapeutics, Inc. (edgar:737207) Net Income: -1571000 USD Concept: fundies:NetIncome Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T18:00:40Z Snapshot: d3571f4524df1cd7e461d9afe846975e6d696a6480f33c0e7aa5556fa861d83f Dimensions: Consolidated View: https://fundies.io/companies/edgar/737207/explain?concept=fundies%3ANetIncome&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=USD&dimensions= Input fundies:NetIncome: -1571000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/737207/000157104915007124/mrna-20150630.xml#170291 Filing: 000157104915007124 The citation records this snapshot. The page link may show a newer release later.	USD 285,000 Exact value Exact value: 285000 USD 2013-01-01 – 2013-12-31: 285000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Adhera Therapeutics, Inc. · 2013-12-31 Adhera Therapeutics, Inc. (edgar:737207) Operating Cash Flow: 285000 USD Concept: fundies:OperatingCashFlow Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T18:00:40Z Snapshot: d3571f4524df1cd7e461d9afe846975e6d696a6480f33c0e7aa5556fa861d83f Dimensions: Consolidated View: https://fundies.io/companies/edgar/737207/explain?concept=fundies%3AOperatingCashFlow&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 285000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/737207/000157104915007124/mrna-20150630.xml#196842 Filing: 000157104915007124 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2014 2014-01-01 – 2014-12-31	−USD 6.48 million Exact value Exact value: -6477000 USD 2014-01-01 – 2014-12-31: -6477000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Adhera Therapeutics, Inc. · 2014-12-31 Adhera Therapeutics, Inc. (edgar:737207) Net Income: -6477000 USD Concept: fundies:NetIncome Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T18:00:40Z Snapshot: d3571f4524df1cd7e461d9afe846975e6d696a6480f33c0e7aa5556fa861d83f Dimensions: Consolidated View: https://fundies.io/companies/edgar/737207/explain?concept=fundies%3ANetIncome&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:NetIncome: -6477000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/737207/000157104916013489/mrna-20151231.xml#126043 Filing: 000157104916013489 The citation records this snapshot. The page link may show a newer release later.	−USD 4.78 million Exact value Exact value: -4779000 USD 2014-01-01 – 2014-12-31: -4779000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Adhera Therapeutics, Inc. · 2014-12-31 Adhera Therapeutics, Inc. (edgar:737207) Operating Cash Flow: -4779000 USD Concept: fundies:OperatingCashFlow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T18:00:40Z Snapshot: d3571f4524df1cd7e461d9afe846975e6d696a6480f33c0e7aa5556fa861d83f Dimensions: Consolidated View: https://fundies.io/companies/edgar/737207/explain?concept=fundies%3AOperatingCashFlow&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -4779000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/737207/000157104916013489/mrna-20151231.xml#148597 Filing: 000157104916013489 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2015 2015-01-01 – 2015-12-31	−USD 1.11 million Exact value Exact value: -1108564 USD 2015-01-01 – 2015-12-31: -1108564 USD Inspect Net Income Open source Share or cite Citation for Net Income · Adhera Therapeutics, Inc. · 2015-12-31 Adhera Therapeutics, Inc. (edgar:737207) Net Income: -1108564 USD Concept: fundies:NetIncome Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T18:00:40Z Snapshot: d3571f4524df1cd7e461d9afe846975e6d696a6480f33c0e7aa5556fa861d83f Dimensions: Consolidated View: https://fundies.io/companies/edgar/737207/explain?concept=fundies%3ANetIncome&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:NetIncome: -1108564 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/737207/000149315217005951/mrna-20170331.xml#135519 Filing: 000149315217005951 The citation records this snapshot. The page link may show a newer release later.	−USD 738,152 Exact value Exact value: -738152 USD 2015-01-01 – 2015-12-31: -738152 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Adhera Therapeutics, Inc. · 2015-12-31 Adhera Therapeutics, Inc. (edgar:737207) Operating Cash Flow: -738152 USD Concept: fundies:OperatingCashFlow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T18:00:40Z Snapshot: d3571f4524df1cd7e461d9afe846975e6d696a6480f33c0e7aa5556fa861d83f Dimensions: Consolidated View: https://fundies.io/companies/edgar/737207/explain?concept=fundies%3AOperatingCashFlow&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -738152 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/737207/000149315217005951/mrna-20170331.xml#479488 Filing: 000149315217005951 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2016 2016-01-01 – 2016-12-31	−USD 837,143 Exact value Exact value: -837143 USD 2016-01-01 – 2016-12-31: -837143 USD Inspect Net Income Open source Share or cite Citation for Net Income · Adhera Therapeutics, Inc. · 2016-12-31 Adhera Therapeutics, Inc. (edgar:737207) Net Income: -837143 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T18:00:40Z Snapshot: d3571f4524df1cd7e461d9afe846975e6d696a6480f33c0e7aa5556fa861d83f Dimensions: Consolidated View: https://fundies.io/companies/edgar/737207/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -837143 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/737207/000149315218005372/mrna-20171231.xml#115730 Filing: 000149315218005372 The citation records this snapshot. The page link may show a newer release later.	−USD 522,314 Exact value Exact value: -522314 USD 2016-01-01 – 2016-12-31: -522314 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Adhera Therapeutics, Inc. · 2016-12-31 Adhera Therapeutics, Inc. (edgar:737207) Operating Cash Flow: -522314 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T18:00:40Z Snapshot: d3571f4524df1cd7e461d9afe846975e6d696a6480f33c0e7aa5556fa861d83f Dimensions: Consolidated View: https://fundies.io/companies/edgar/737207/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -522314 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/737207/000149315218005372/mrna-20171231.xml#334622 Filing: 000149315218005372 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2017 2017-01-01 – 2017-12-31	−USD 6.22 million Exact value Exact value: -6219348 USD 2017-01-01 – 2017-12-31: -6219348 USD Inspect Net Income Open source Share or cite Citation for Net Income · Adhera Therapeutics, Inc. · 2017-12-31 Adhera Therapeutics, Inc. (edgar:737207) Net Income: -6219348 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T18:00:40Z Snapshot: d3571f4524df1cd7e461d9afe846975e6d696a6480f33c0e7aa5556fa861d83f Dimensions: Consolidated View: https://fundies.io/companies/edgar/737207/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -6219348 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/737207/000149315219005482/atrx-20181231.xml#158371 Filing: 000149315219005482 The citation records this snapshot. The page link may show a newer release later.	−USD 1.26 million Exact value Exact value: -1260685 USD 2017-01-01 – 2017-12-31: -1260685 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Adhera Therapeutics, Inc. · 2017-12-31 Adhera Therapeutics, Inc. (edgar:737207) Operating Cash Flow: -1260685 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T18:00:40Z Snapshot: d3571f4524df1cd7e461d9afe846975e6d696a6480f33c0e7aa5556fa861d83f Dimensions: Consolidated View: https://fundies.io/companies/edgar/737207/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -1260685 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/737207/000149315219005482/atrx-20181231.xml#317888 Filing: 000149315219005482 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2018 2018-01-01 – 2018-12-31	−USD 16.76 million Exact value Exact value: -16755000 USD 2018-01-01 – 2018-12-31: -16755000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Adhera Therapeutics, Inc. · 2018-12-31 Adhera Therapeutics, Inc. (edgar:737207) Net Income: -16755000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T18:00:40Z Snapshot: d3571f4524df1cd7e461d9afe846975e6d696a6480f33c0e7aa5556fa861d83f Dimensions: Consolidated View: https://fundies.io/companies/edgar/737207/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -16755000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/737207/000073720720000006/atrx-20191231x10k.htm#1337107 Filing: 000073720720000006 The citation records this snapshot. The page link may show a newer release later.	−USD 9.61 million Exact value Exact value: -9611000 USD 2018-01-01 – 2018-12-31: -9611000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Adhera Therapeutics, Inc. · 2018-12-31 Adhera Therapeutics, Inc. (edgar:737207) Operating Cash Flow: -9611000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T18:00:40Z Snapshot: d3571f4524df1cd7e461d9afe846975e6d696a6480f33c0e7aa5556fa861d83f Dimensions: Consolidated View: https://fundies.io/companies/edgar/737207/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -9611000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/737207/000073720720000006/atrx-20191231x10k.htm#1232083 Filing: 000073720720000006 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2019 2019-01-01 – 2019-12-31	−USD 11.98 million Exact value Exact value: -11978000 USD 2019-01-01 – 2019-12-31: -11978000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Adhera Therapeutics, Inc. · 2019-12-31 Adhera Therapeutics, Inc. (edgar:737207) Net Income: -11978000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T18:00:40Z Snapshot: d3571f4524df1cd7e461d9afe846975e6d696a6480f33c0e7aa5556fa861d83f Dimensions: Consolidated View: https://fundies.io/companies/edgar/737207/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -11978000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/737207/000149315221008190/form10-k.htm#936440 Filing: 000149315221008190 The citation records this snapshot. The page link may show a newer release later.	−USD 8.74 million Exact value Exact value: -8738000 USD 2019-01-01 – 2019-12-31: -8738000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Adhera Therapeutics, Inc. · 2019-12-31 Adhera Therapeutics, Inc. (edgar:737207) Operating Cash Flow: -8738000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T18:00:40Z Snapshot: d3571f4524df1cd7e461d9afe846975e6d696a6480f33c0e7aa5556fa861d83f Dimensions: Consolidated View: https://fundies.io/companies/edgar/737207/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -8738000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/737207/000149315221008190/form10-k.htm#860493 Filing: 000149315221008190 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2020 2020-01-01 – 2020-12-31	−USD 3.77 million Exact value Exact value: -3766000 USD 2020-01-01 – 2020-12-31: -3766000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Adhera Therapeutics, Inc. · 2020-12-31 Adhera Therapeutics, Inc. (edgar:737207) Net Income: -3766000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T18:00:40Z Snapshot: d3571f4524df1cd7e461d9afe846975e6d696a6480f33c0e7aa5556fa861d83f Dimensions: Consolidated View: https://fundies.io/companies/edgar/737207/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -3766000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/737207/000149315222034344/forms-1.htm#2086794 Filing: 000149315222034344 The citation records this snapshot. The page link may show a newer release later.	−USD 588,000 Exact value Exact value: -588000 USD 2020-01-01 – 2020-12-31: -588000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Adhera Therapeutics, Inc. · 2020-12-31 Adhera Therapeutics, Inc. (edgar:737207) Operating Cash Flow: -588000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T18:00:40Z Snapshot: d3571f4524df1cd7e461d9afe846975e6d696a6480f33c0e7aa5556fa861d83f Dimensions: Consolidated View: https://fundies.io/companies/edgar/737207/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -588000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/737207/000149315222034344/forms-1.htm#1923775 Filing: 000149315222034344 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2021 2021-01-01 – 2021-12-31	−USD 6.35 million Exact value Exact value: -6351000 USD 2021-01-01 – 2021-12-31: -6351000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Adhera Therapeutics, Inc. · 2021-12-31 Adhera Therapeutics, Inc. (edgar:737207) Net Income: -6351000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T18:00:40Z Snapshot: d3571f4524df1cd7e461d9afe846975e6d696a6480f33c0e7aa5556fa861d83f Dimensions: Consolidated View: https://fundies.io/companies/edgar/737207/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -6351000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/737207/000149315223010160/form10-k.htm#1415523 Filing: 000149315223010160 The citation records this snapshot. The page link may show a newer release later.	−USD 665,000 Exact value Exact value: -665000 USD 2021-01-01 – 2021-12-31: -665000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Adhera Therapeutics, Inc. · 2021-12-31 Adhera Therapeutics, Inc. (edgar:737207) Operating Cash Flow: -665000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T18:00:40Z Snapshot: d3571f4524df1cd7e461d9afe846975e6d696a6480f33c0e7aa5556fa861d83f Dimensions: Consolidated View: https://fundies.io/companies/edgar/737207/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -665000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/737207/000149315223010160/form10-k.htm#1266795 Filing: 000149315223010160 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2022 2022-01-01 – 2022-12-31	−USD 2.11 million Exact value Exact value: -2114000 USD 2022-01-01 – 2022-12-31: -2114000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Adhera Therapeutics, Inc. · 2022-12-31 Adhera Therapeutics, Inc. (edgar:737207) Net Income: -2114000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T18:00:40Z Snapshot: d3571f4524df1cd7e461d9afe846975e6d696a6480f33c0e7aa5556fa861d83f Dimensions: Consolidated View: https://fundies.io/companies/edgar/737207/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -2114000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/737207/000149315223010160/form10-k.htm#1415165 Filing: 000149315223010160 The citation records this snapshot. The page link may show a newer release later.	−USD 1.4 million Exact value Exact value: -1400000 USD 2022-01-01 – 2022-12-31: -1400000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Adhera Therapeutics, Inc. · 2022-12-31 Adhera Therapeutics, Inc. (edgar:737207) Operating Cash Flow: -1400000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T18:00:40Z Snapshot: d3571f4524df1cd7e461d9afe846975e6d696a6480f33c0e7aa5556fa861d83f Dimensions: Consolidated View: https://fundies.io/companies/edgar/737207/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -1400000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/737207/000149315223010160/form10-k.htm#1307610 Filing: 000149315223010160 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

163 filings · 2,510 latest values · 2,510 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0000737207, 737207, ATRX, MRNA, edgar:737207, mrna

Also known as ADHERA THERAPEUTICS, INC., ADHERA THERAPEUTICS, INC., Adhera Therapeutics, Inc., MARINA BIOTECH, INC., MDRNA, Inc., Marina Biotech, Inc., NASTECH PHARMACEUTICAL CO INC

Adhera Therapeutics, Inc.

Latest quarter

Revenue

Operating cash flow

Reported share-count change

Trailing twelve months

Revenue

Company performance

What changed year over year

Net income

Operating cash flow

Where revenue goes

2019 2019-01-01 – 2019-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation